The Variable Clinical Picture of Drug-Induced Hypersensitivity Syndrome/Drug Rash with Eosinophilia and Systemic Symptoms in Relation to the Eliciting Drug
Section snippets
Diagnosis of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms
The criteria for the diagnosis of DRESS proposed by Bocquet and colleagues4 are as follows: (1) cutaneous drug eruption; (2) hematologic abnormalities, including eosinophilia greater than 1.5 × 109 eosinophils/L or the presence of atypical lymphocytes; and (3) systemic involvement, including adenopathies greater than 2 cm in diameter, hepatitis (liver transaminases values >2 N), interstitial nephritis, interstitial pneumonia, or carditis. The criteria emphasize two important characteristics:
Characteristics of the causative drugs
DIHS/DRESS is caused by a limited number of specific drugs, such as anticonvulsants, allopurinol, and sulfonamides. Box 3 lists drugs that reportedly cause DIHS/DRESS. It remains unknown, however, why a limited number of drugs can cause the development of DIHS/DRESS because they do not have any pharmacologic actions or structural similarities in common.
Various factors may contribute to the development of DIHS/DRESS. The authors have demonstrated that there is a decrease in serum immunoglobulin
Aromatic Anticonvulsants
Anticonvulsant hypersensitivity syndrome is a life-threatening syndrome that occurs after exposure to aromatic anticonvulsants, including CBZ, phenytoin, and phenobarbital. The incidence of this syndrome induced by these anticonvulsants is thought to be in the range of 1 per 1000 to 10,000 exposures.2 Cross-reactivity between CBZ, phenytoin, and phenobarbital may be as high as 70% to 80%;25 this may explain why symptoms persist or recur after switching to another aromatic anticonvulsant. In
Summary
DIHS/DRESS exhibits a broad range of clinical manifestations and laboratory abnormalities that are a result of the interplay of host immune status, the extent of sensitization to the drug, immunologic and pharmacokinetic properties of the drug, and the sites and types of viral reactions associated with this syndrome. They could also induce reactions with a different time sequence. Despite a variable clinical appearance, however, DIHS/DRESS is a distinct clinical entity with highly reproducible
References (68)
- et al.
Familial occurrence of hypersensitivity to phenytoin
Am J Med
(1991) Clinical heterogeneity of drug hypersensitivity
Toxicology
(2005)- et al.
Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy
J Am Acad Dermatol
(1991) - et al.
Hypogammaglobulinemia as an early sign of drug-induced hypersensitivity syndrome
J Am Acad Dermatol
(2006) - et al.
The effect of phenytoin in vitro on normal human mononuclear cells and on human lymphoblastoid B cell lines of different Ig isotype specificities
Immunobiology
(1985) Carbamazepine-induced IgG1 and IgG2 deficiency associated with B cell maturation defect
Seizure
(2004)- et al.
Mexiletine-induced severe skin eruption, fever, eosinophilia, lymphocytosis, and liver dysfunction
Pain
(1997) - et al.
Clomipramine-induced hypersensitivity syndrome with unusual clinical features
J Am Acad Dermatol
(2005) - et al.
The drug hypersensitivity syndrome: what is the pathogenesis?
Arch Dermatol
(2001) - et al.
Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome
Dermatol Online J
(2002)
Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)
Semin Cutan Med Surg
Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome
Br J Dermatol
Human herpesvirus 6 infection as a risk factor of the development of severe drug-induced hypersensitivity
Arch Dermatol
Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6
Arch Dermatol
Human herpesvirus 6 and drug allergy
Curr Opin Allergy Clin Immunol
The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations
Br J Dermatol
Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease
Br J Dermatol
Drug-induced hypersensitivity syndrome and viral reactivation
Drug-induced pseudolymphoma and hypersensitivity syndrome; two different clinical entities
Arch Dermatol
Cutaneous pseudo-T cell lymphomas; a clinicopathologic study of 20 patients
Cancer
Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome
Acta Derm Venereol
Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome
JAMA
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?
Br J Dermatol
Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia
Arch Dermatol
Association of hypogammaglobulinemia with DRESS (drug rash with eosinophilia and systemic symptoms)
Eur J Dermatol
A complex interaction between drug allergy and viral infection
Clin Rev Allergy Immunol
Anticonvulsant hypersensitivity syndrome: incidence, prevention and management
Drug Saf
Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review
Int J Dermatol
Serious drug reactions to carbamazepine in oncologic patients after x-ray treatment: report of four cases
Acta Dermatovenerol Alp Panonica Adriat
Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk
J Clin Invest
Impact of phenytoin therapy on the skin and skin disease
Expert Opin Drug Saf
Dilantin hypersensitivity syndrome imitating staphylococcal toxic shock
Arch Dermatol
Dilantin hypersensitivity reaction
Cutis
Diphenylhydantoin-induced hepatitis
Ann Allergy
Cited by (147)
Fever and Rash
2024, Emergency Medicine Clinics of North AmericaDRESS syndrome in 2023
2023, Bulletin de l'Academie Nationale de MedecineDRESS, the maverick among SCARS: A case series-based review of literature
2023, Medical Journal Armed Forces IndiaA fatal presentation of DRESS syndrome with multiple visceral failure mimicking septic shock
2022, Annals of Medicine and SurgeryCitation Excerpt :After 3 days of his admission, the patient recovered his renal function with a good clinico-biological evolution, and a complete weaning of the drugs, and then the patient is transferred in service of rheumatology for adjustment of his hypourecemiant treatment. The term DRESS (drug rush with eosinophilia and systemic symptoms) was initially introduced by bocquet [1], later we realized that it was a systemic reaction so it changed to DRESS (drug reaction with eosinophilia and systemic symptoms) [2], in fact the first symptoms were described in cases induced by anticonvulsant such us carbamazepine and dress syndrome was called at that time AHS (anticonvulsant hypersensivity syndrome) [3] The incidence of DRESS syndrome varies between 1/1000 and 1/10000 [4] with a mortality of 10–20% [5]. The clinical presentation of dress is predominantly cutaneous, with or without visceral involvement, with fever, adenopathy, elevated white blood count, and abnormal liver function.
This work was supported in part by grants from the Ministry of Education, Sports, Science, and Culture of Japan (to Y.K. and T.S.) and Health and Labo Sciences Research grants from the Ministry of Health, Labor, and Welfare of Japan (to T.S.).